Interferon Tau Affects Mouse Intestinal Microbiota and Expression of IL-17

Mediators of Inflammation

Volumn 2016, Issue , 2016, Pages

  Ren, Wenkai ^a,b   Chen, Shuai ^a   Zhang, Liwen ^c   Liu, Gang ^a   Hussain, Tarique ^a   Hao, Xiao ^a   Yin, Jie ^a   Duan, Jielin ^a   Tan, Bie ^a   Wu, Guoyao ^d   Bazer, Fuller W ^d   Yin, Yulong ^a  

^a INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c Jinan Seventh People s Hospital   (China)

^d TEXAS A AND M UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CRYPTIDIN 1; CRYPTIDIN 4; CRYPTIDIN 5; DNA 16S; GAMMA INTERFERON; IMMUNOGLOBULIN J CHAIN; INTERLEUKIN 17; LYSOZYME; MUCIN 4; PROTEIN; SECRETORY COMPONENT; TAU INTERFERON; UNCLASSIFIED DRUG; INTERFERON; PLACENTA PROTEIN; RIBOSOME DNA; TROPHOBLAST PROTEIN 1;

ALLOPREVOTELLA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTEROIDES; BACTEROIDETES; BLAUTIA; BODY WEIGHT; CANDIDATUS; COLON; CONTROLLED STUDY; DESULFOVIBRIO; ENTERORHABDUS; FECES; FECES MICROFLORA; FIRMICUTES; FLUID INTAKE; FOOD INTAKE; ILEUM; INNATE IMMUNITY; INTESTINE FLORA; JEJUNUM; LACTOBACILLUS; MICROBIAL DIVERSITY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEOBACTERIA; SACCHARIMONAS; SUPPLEMENTATION; ANIMAL; DRUG EFFECTS; EATING; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; DNA, RIBOSOMAL; EATING; GASTROINTESTINAL MICROBIOME; INTERFERON TYPE I; INTERLEUKIN-17; MICE; PREGNANCY PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84984851216     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2016/2839232     Document Type: Article

References (40)

1. K. Brooks and T. E. Spencer, "Biological roles of interferon tau (IFNT) and type I IFN receptors in elongation of the ovine conceptus, " Biology of Reproduction, vol. 92, article 47, 2015.
2. F. W. Bazer, W. Ying, X. Wang et al., "The many faces of interferon tau, " Amino Acids, vol. 47, no. 3, pp. 449-460, 2015.
3. A. P. Alexenko, A. D. Ealy, and R. M. Roberts, "The cross-species antiviral activities of different IFN-tau subtypes on bovine, murine, and human cells: contradictory evidence for therapeutic potential, " Journal of Interferon & Cytokine Research, vol. 19, no. 12, pp. 1335-1341, 1999.
4. K. Hara, K. Shirasuna, F. Usui et al., "Interferon-tau attenuates uptake of nanoparticles and secretion of interleukin-1αin macrophages, " PLoSONE, vol. 9, no. 12, Article IDe113974, 2014.
5. W. Ying, S. Kanameni, C.-A. Chang et al., "Interferon tau alleviates obesity-induced adipose tissue inflammation and insulin resistance by regulatingmacrophage polarization, " PLoS ONE, vol. 9, no. 6, Article ID e98835, 2014.
6. J. M. González-Navajas, J. Lee, M. David, and E. Raz, "Immunomodulatory functions of type i interferons, " Nature Reviews Immunology, vol. 12, no. 2, pp. 125-135, 2012.
7. L. Boscá, O. G. Bodelón, S. Hortelano, A. Casellas, and F. Bosch, "Anti-inflammatory action of type I interferons deduced from mice expressing interferon, " Gene Therapy, vol. 7, no. 10, pp. 817-825, 2000.
8. D. J. Gough, N. L. Messina, C. J. P. Clarke, R. W. Johnstone, and D. E. Levy, "Constitutive type I interferon modulates homeostatic balance through tonic signaling, " Immunity, vol. 36, no. 2, pp. 166-174, 2012.
9. J. M. Soos, O. Stüve, S. Youssef et al., "Cutting edge: oral type I IFN-αpromotes a Th2 bias and enhances suppression of autoimmune encephalomyelitis by oral glatiramer acetate, " The Journal of Immunology, vol. 169, no. 5, pp. 2231-2235, 2002.
10. M. Inoue and M. L. Shinohara, "The role of interferon-αin the treatment of multiple sclerosis and experimental autoimmune encephalomyelitis-in the perspective of inflammasomes, " Immunology, vol. 139, no. 1, pp. 11-18, 2013.
11. C. H. Pontzer, F. W. Bazer, and H. M. Johnson, "Antiproliferative activity of a pregnancy recognition hormone, ovine trophoblast protein-1, " Cancer Research, vol. 51, no. 19, pp. 5304-5307, 1991.
12. J. M. Soos, P. S. Subramaniam, A. C. Hobeika, J. Schiffenbauer, and H. M. Johnson, "The IFN pregnancy recognition hormone IFN-αblocks both development and superantigen reactivation of experimental allergic encephalomyelitis without associated toxicity, " Journal of Immunology, vol. 155, no. 5, pp. 2747-2753, 1995.
13. B. Chassaing, O. Koren, J. K. Goodrich et al., "Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome, " Nature, vol. 519, no. 7541, pp. 92-96, 2015.
14. C. E. West, H. Renz, M. C. Jenmalm et al., "The gut microbiota and inflammatory noncommunicable diseases: associations and potentials for gut microbiota therapies, " Journal of Allergy and Clinical Immunology, vol. 135, no. 1, pp. 3-14, 2015.
15. W. Ouyang, J. K. Kolls, and Y. Zheng, "The biological functions of T helper 17 cell effector cytokines in inflammation, " Immunity, vol. 28, no. 4, pp. 454-467, 2008.
16. T. Koga, C. M. Hedrich, M. Mizui et al., "CaMK4-dependent activation of AKT/mTOR and CREM-αunderlies autoimmunity-associated Th17 imbalance, " Journal of Clinical Investigation, vol. 124, no. 5, pp. 2234-2245, 2014.
17. W. Ren, G. Liu, J. Yin et al., "Draft genome sequence of enterotoxigenic Escherichia coli strain W25K, " Genome Announcements, vol. 2, no. 3, Article ID e00593-14, 2014.
18. W. Ren, S. Chen, J. Yin et al., "Dietary arginine supplementation of mice alters the microbial population and activates intestinal innate immunity, " Journal of Nutrition, vol. 144, no. 6, pp. 988-995, 2014.
19. C. D. Tekwe, J. Lei, K. Yao et al., "Oral administration of interferon tau enhances oxidation of energy substrates and reduces adiposity in Zucker diabetic fatty rats, " BioFactors, vol. 39, no. 5, pp. 552-563, 2013.
20. J. Gibson, S. Shokralla, T. M. Porter et al., "Simultaneous assessment of the macrobiome and microbiome in a bulk sample of tropical arthropods through DNA metasystematics, " Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 22, pp. 8007-8012, 2014.
21. W. Ren, J. Duan, J. Yin et al., "Dietary l-glutamine supplementation modulates microbial community and activates innate immunity in the mouse intestine, " Amino Acids, vol. 46, no. 10, pp. 2403-2413, 2014.
22. W.-J. Lee and K. Hase, "Gut microbiota-generated metabolites in animal health and disease, " Nature Chemical Biology, vol. 10, no. 6, pp. 416-424, 2014.
23. S. Subramanian, S. Huq, T. Yatsunenko et al., "Persistent gut microbiota immaturity inmalnourished Bangladeshi children, " Nature, vol. 510, no. 7505, pp. 417-421, 2014.
24. F. F. Anhê, D. Roy, G. Pilon et al., "A polyphenol-rich cranberry extract protects from diet-induced obesity, insulin resistance and intestinal inflammation in association with increased Akkermansia spp. population in the gut microbiota of mice, " Gut, vol. 64, no. 6, pp. 872-883, 2015.
25. P. Louis, G. L. Hold, and H. J. Flint, "The gut microbiota, bacterial metabolites and colorectal cancer, " Nature Reviews Microbiology, vol. 12, no. 10, pp. 661-672, 2014.
26. N. Qin, F. Yang, A. Li et al., "Alterations of the human gut microbiome in liver cirrhosis, " Nature, vol. 513, no. 7516, pp. 59-64, 2014.
27. P. J. Turnbaugh, R. E. Ley, M. A. Mahowald, V. Magrini, E. R. Mardis, and J. I. Gordon, "An obesity-associated gut microbiomewith increased capacity for energy harvest, " Nature, vol. 444, no. 7122, pp. 1027-1031, 2006.
28. R. E. Ley, P. J. Turnbaugh, S. Klein, and J. I. Gordon, "Microbial ecology: human gut microbes associated with obesity, " Nature, vol. 444, no. 7122, pp. 1022-1023, 2006.
29. V. Liévin-Le Moal and A. L. Servin, "Anti-infective activities of Lactobacillus strains in the human intestinal microbiota: from probiotics to gastrointestinal anti-infectious biotherapeutic agents, " ClinicalMicrobiology Reviews, vol. 27, no. 2, pp. 167-199, 2014.
30. A. Marcobal and J. L. Sonnenburg, "Human milk oligosaccharide consumption by intestinal microbiota, " Clinical Microbiology and Infection, vol. 18, supplement 4, pp. 12-15, 2012.
31. A. G. Shabgah, E. Fattahi, and F. Z. Shahneh, "Interleukin-17 in human inflammatory diseases, " Postepy Dermatologii i Alergologii, vol. 31, no. 4, pp. 256-261, 2014.
32. S. H. Chang and C. Dong, "Signaling of interleukin-17 family cytokines in immunity and inflammation, " Cellular Signalling, vol. 23, no. 7, pp. 1069-1075, 2011.
33. M. F. Gulen, Z. Kang, K. Bulek et al., "The receptor SIGIRR suppressesTh17 cell proliferation via inhibition of the interleukin-1 receptor pathway and mTOR kinase activation, " Immunity, vol. 32, no. 1, pp. 54-66, 2010.
34. J. S. Kim, T. Sklarz, L. B. Banks et al., "Natural and inducible TH17 cells are regulated differently by Akt and mTOR pathways, " Nature Immunology, vol. 14, no. 6, pp. 611-618, 2013.
35. Y. Park, H.-S. Jin, J. Lopez et al., "TSC1 regulates the balance between effector and regulatory T cells, "The Journal of Clinical Investigation, vol. 123, no. 12, pp. 5165-5178, 2013.
36. S. Nagai, Y. Kurebayashi, and S. Koyasu, "Role of PI3K/Akt and mTOR complexes inTh17 cell differentiation, " Annals of theNew York Academy of Sciences, vol. 1280, no. 1, pp. 30-34, 2013.
37. W. Ren, J. Yin, J. Duan et al., "mTORC1 signaling and IL-17 expression: defining pathways and possible therapeutic targets, " European Journal of Immunology, vol. 46, no. 2, pp. 291-299, 2016.
38. Y. Kurebayashi, S. Nagai, A. Ikejiri et al., "PI3K-Akt-mTORC1-S6K1/2 axis controls Th17 differentiation by regulating Gfi1 expression and nuclear translocation of ROR, " Cell Reports, vol. 1, no. 4, pp. 360-373, 2012.
39. L. Z. Shi, R. Wang, G. Huang et al., "HIF1α-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells, " The Journal of Experimental Medicine, vol. 208, no. 7, pp. 1367-1376, 2011.
40. E. V. Dang, J. Barbi, H.-Y. Yang et al., "Control of TH17/Treg balance by hypoxia-inducible factor 1, " Cell, vol. 146, no. 5, pp. 772-784, 2011.